Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

Pharma is not interested in 7 million euros

Written by DS on in the category news with the tags .


Since the end of 2014, pharmaceutical companies have the possibility to submit an application to the Riziv/Inami to obtain funds to make new medicines accessible faster for patients, for diseases for which no treatment exists. Although 7 million euro is ready available, no company seems to be interested.

Pharmaceutical companies can file an application with Riziv/Inami to obtain an accelerated contribution for an innovative drug, even before registration and regularization of reimbursement of the drug. In this way, the government tries to get new agents that treat a serious disease two years faster to patients.

However, eight months after the start of the project no company submitted a dossier. "Apparently, the pharmaceutical industry has adopted a wait and see attitude," said Ri De Ridder of Riziv/Inami.

It is not entirely clear why no companies have tried to make use of this opportunity. Stefaan Fiers, spokesman for pharma.be, suspects that the conditions to obtain funds are not clear enough. It is true that the early reimbursement of the holding also requires a financial effort.

(Source: Het Nieuwsblad)

Read more about: .

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Turnstone V-Bio Ventures KU Leuven GSK XpandInnovation Itera Life Science Janssen Flanders.bio UGent Biowin

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.